• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Health

We were promised Pfizer pills. Where are the other COVID treatments?

Nicole Goodkind
By
Nicole Goodkind
Nicole Goodkind
Down Arrow Button Icon
Nicole Goodkind
By
Nicole Goodkind
Nicole Goodkind
Down Arrow Button Icon
January 11, 2022, 5:02 PM ET

U.S. COVID-19 cases have reached record highs, and so have hospitalizations. Two years after the first patient was diagnosed on American soil, the pandemic appears to show no signs of slowing down. 

More than 145,900 people were hospitalized with the virus as of Tuesday, according to data from the Department of Health and Human Services. That’s a 100% increase in two weeks and a record high, surpassing the previous peak in January 2021. 

At the beginning of the surge, there was hope that a new group of antiviral drugs could help quell the rush of Omicron across the country. The Food and Drug Administration issued emergency use authorization (EUA) for Pfizer’s Paxlovid, which the company says cuts the risk of hospitalization or death by 89%, and Merck’s molnupiravir, which data showed cut hospitalization or death by 30%. 

Both regimens are for patients with mild to moderate COVID and require 30 to 40 pills to be taken at home over the course of five days.

The U.S. purchased 10 million courses of Pfizer’s treatment in a $5 billion deal (officials announced this week that they would order 10 million more) and 3 million courses of Merck’s treatment for $2.2 billion. However, supplies of the pills are extremely limited compared with preventative treatments like vaccines; the U.S. ordered 100 million doses each of the Moderna and Pfizer vaccines prior to when they launched.

And no matter how potent the new antiviral drugs might be, shortages and supply-chain issues have rendered them relatively ineffective, doctors say. Even considering relatively small orders of a few million, as of last week, only about 365,000 courses of the Pfizer and Merck pills had shipped out, though President Joe Biden assured more were coming. 

Because of the complexity of the medicines, explained Biden at a press conference last week, “it takes months literally to make a pill.” 

The Mountain Comprehensive Health Center in Kentucky, a state in which just 55% of people are fully vaccinated, received only 200 treatment courses of the Merck antiviral and 40 of the Pfizer antiviral this week. 

“Basically, it’s just a drop in the bucket,” Mike Caudill, CEO of Mountain Comprehensive, which serves 50,000 patients in seven counties, told the Louisville Courier Journal. “We’re going to try to use it in such a way to treat people at extreme risk.”

Will Harper, a spokesman for Contra Costa Health Services in San Francisco, echoed that view, and even used the same language. 

“At this point, there’s simply not enough of it for it to be a game changer,” he told theSan Francisco Chronicle, adding that “120 courses is a drop in the bucket when we are seeing more than 1,300 new COVID cases each day.”

The rate of increase in COVID-19 cases far outstrips the rate at which the antiviral medications, the allocation of which is being managed by the federal government’s Office of the Assistant Secretary for Preparedness and Response, can be produced and shipped out. 

Dr. Anthony Fauci, the president’s chief medical adviser, echoed Biden’s explanation about the lengthy pill-making process as explanation for the delay. “The sobering news is, unfortunately, it is really a quite complicated and complex synthetic process, which we will be working with the company to figure out how we can help alleviate the stress of the long duration that it takes to make it,” he said at a press briefing late last month. “Hopefully we’ll be able to shorten that process.”

Vaccinations and boosters have protected against the severity of Omicron (ICUs are not as busy as they were during previous spikes), but many Americans are still experiencing symptoms that require hospitalization, and health care systems are overwhelmed. Death rates are also typically a lagging indicator of severity of illness, and while they’re still far from record highs, they’ve increased by 31% nationwide over the past week. 

About a quarter of hospitals in the U.S. are now experiencing critical staffing shortages, according to the Department of Health and Human Services. Some states, like ​​Illinois and Massachusetts, have delayed elective surgeries. Oregon deployed the National Guard to help in hospitals. Maryland Gov. Larry Hogan, declared a state of emergency last week, and warned that this will be the “most challenging time of the entire pandemic.” 

Health care workers in Arizona, meanwhile, told state leaders that their health care system is on the brink of collapse. “We’ve had more events where people are having cardiac arrests, or decompensating and getting very sick and even dying in the waiting rooms,” Dr. Bradley Dreifuss, an emergency medicine physician in Tucson, told reporters on Friday. Americans, meanwhile, appear to be losing hope for a miracle cure or treatment. A new Axios/Ipsos poll found that 52% of respondents believe it will be more than a year—or never—before they can return to their normal, pre-COVID lives.

Never miss a story: Follow your favorite topics and authors to get a personalized email with the journalism that matters most to you.

About the Author
Nicole Goodkind
By Nicole Goodkind
LinkedIn iconTwitter icon
See full bioRight Arrow Button Icon

Latest in Health

HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
8 hours ago
Julian Braithwaite is the Director General of the International Alliance for Responsible Drinking
CommentaryProductivity
Gen Z is drinking 20% less than Millennials. Productivity is rising. Coincidence? Not quite
By Julian BraithwaiteDecember 13, 2025
9 hours ago
Nicholas Thompson
C-SuiteBook Excerpt
I took over one of the most prestigious media firms while training for an ultramarathon. Here’s what I learned becoming CEO of The Atlantic
By Nicholas ThompsonDecember 13, 2025
11 hours ago
Healthmeal delivery
Factor Meals Review 2025: Tester Approved
By Christina SnyderDecember 12, 2025
1 day ago
Donald Trump
HealthHealth Insurance
‘Tragedy in the making’: Top healthcare exec on why insurance will spike to subsidize a tax cut to millionaires and billionaires
By Nick LichtenbergDecember 12, 2025
1 day ago
HelloFresh meal delivery service.
Healthmeal delivery
HelloFresh Review : We Tasted Everything so You Don’t Have To
By Christina SnyderDecember 12, 2025
1 day ago

Most Popular

placeholder alt text
Economy
Tariffs are taxes and they were used to finance the federal government until the 1913 income tax. A top economist breaks it down
By Kent JonesDecember 12, 2025
2 days ago
placeholder alt text
Success
Apple cofounder Ronald Wayne sold his 10% stake for $800 in 1976—today it’d be worth up to $400 billion
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Success
40% of Stanford undergrads receive disability accommodations—but it’s become a college-wide phenomenon as Gen Z try to succeed in the current climate
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Economy
The Fed just ‘Trump-proofed’ itself with a unanimous move to preempt a potential leadership shake-up
By Jason MaDecember 12, 2025
1 day ago
placeholder alt text
Economy
For the first time since Trump’s tariff rollout, import tax revenue has fallen, threatening his lofty plans to slash the $38 trillion national debt
By Sasha RogelbergDecember 12, 2025
1 day ago
placeholder alt text
Success
Apple CEO Tim Cook out-earns the average American’s salary in just 7 hours—to put that into context, he could buy a new $439,000 home in just 2 days
By Emma BurleighDecember 12, 2025
1 day ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.